Efficacy of β blockers in patients with heart failure plus atrial fibrillation: An individual-patient data meta-analysis

The Lancet

Volumn 384, Issue 9961, 2014, Pages 2235-2243

  Kotecha, Dipak ^a,b,c   Holmes, Jane ^d   Krum, Henry ^c   Altman, Douglas G ^d   Manzano, Luis ^e   Cleland, John G F ^b,f   Lip, Gregory Y H ^a,g   Coats, Andrew J S ^c,h   Andersson, Bert ⁱ   Kirchhof, Paulus ^a,g,j   Von Lueder, Thomas G ^c,k   Wedel, Hans ^l   Rosano, Giuseppe ^m   Shibata, Marcelo C ⁿ   Rigby, Alan ^o   Flather, Marcus D ^p  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e HOSPITAL RAMÓN Y CAJAL   (Spain)

^f UNIVERSITY OF HULL   (United Kingdom)

^g CITY HOSPITAL   (United Kingdom)

^h UNIVERSITY OF WARWICK   (United Kingdom)

ⁱ SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^j UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^k OSLO UNIVERSITY HOSPITAL   (Norway)

^l NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^m IRCCS SAN RAFFAELE PISANA   (Italy)

ⁿ UNIVERSITY OF ALBERTA   (Canada)

^o CASTLE HILL HOSPITAL   (United Kingdom)

^p UNIVERSITY OF EAST ANGLIA   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; COMPLICATION; ELECTROCARDIOGRAPHY; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; LENGTH OF STAY; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA;

ADRENERGIC BETA-ANTAGONISTS; ATRIAL FIBRILLATION; ELECTROCARDIOGRAPHY; HEART FAILURE; HUMANS; LENGTH OF STAY; PATIENT ADMISSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE;

EID: 84919329715     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61373-8     Document Type: Article

References (48)

1. JJ McMurray, S Adamopoulos, SD Anker et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 Eur Heart J 33 2012 1787 1847
2. CW Yancy, M Jessup, B Bozkurt et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 128 2013 e240 e319
3. DS Lee, JV Tu, DN Juurlink et al. Risk-treatment mismatch in the pharmacotherapy of heart failure JAMA 294 2005 1240 1247
4. D Kotecha, L Manzano, DG Altman Individual patient data meta-analysis of beta-blockers in heart failure: rationale and design Syst Rev 2 2013 7
5. AJ Camm, P Kirchhof, GYH Lip et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur Heart J 31 2010 2369 2429
6. PA Heidenreich, JG Trogdon, OA Khavjou et al. Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association Circulation 123 2011 933 944
7. BP Krijthe, A Kunst, EJ Benjamin et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060 Eur Heart J 34 2013 2746751
8. S Colilla, A Crow, W Petkun, DE Singer, T Simon, X Liu Estimates of Current and Future Incidence and Prevalence of Atrial Fibrillation in the U.S. Adult Population Am J Cardiol 112 2013 1142 1147
9. AS Desai, LW Stevenson Rehospitalization for heart failure: predict or prevent? Circulation 126 2012 501 506
10. AN Amin, M Jhaveri, J Lin Hospital readmissions in US atrial fibrillation patients: occurrence and costs Am J Ther 20 2013 143 150
11. F Braunschweig, MR Cowie, A Auricchio What are the costs of heart failure? Europace 13 2011 ii13 ii17
12. D Dries, D Exner, B Gersh, M Domanski, M Waclawiw, L Stevenson Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials J Am Coll Cardiol 32 1998 695 703
13. TJ Wang, MG Larson, D Levy et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study Circulation 107 2003 2920 2925
14. WH Maisel, LW Stevenson Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy Am J Cardiol 91 2003 2D 8D
15. M Rienstra, K Damman, BA Mulder, IC Van Gelder, JJV McMurray, DJ Van Veldhuisen Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis JACC: Heart Failure 1 2013 21 28
16. LA Stewart, JF Tierney To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data Eval Health Prof 25 2002 76 97
17. D Moher, A Liberati, J Tetzlaff, DG Altman Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement BMJ 339 2009 b2535
18. Australia/New Zealand Heart Failure Research Collaborative Group Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease Lancet 349 1997 375 380
19. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure N Engl J Med 344 2001 1659 1667
20. The CAPRICORN Investigators Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial Lancet 357 2001 1385 1390
21. JG Cleland, DJ Pennell, SG Ray et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial Lancet 362 2003 14 21
22. CIBIS Investigators and Committees A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS) Circulation 90 1994 1765 1773
23. CIBIS-II Investigators and Committees The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial Lancet 353 1999 9 13
24. M Packer, AJ Coats, MB Fowler et al. Effect of carvedilol on survival in severe chronic heart failure N Engl J Med 344 2001 1651 1658
25. F Waagstein, MR Bristow, K Swedberg for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy Lancet 342 1993 1441 1446
26. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF Lancet 353 1999 2001 2007
27. MD Flather, MC Shibata, AJ Coats et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) Eur Heart J 26 2005 215 225
28. M Packer, MR Bristow, JN Cohn et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group N Engl J Med 334 1996 1349 1355
29. JPT Higgins, DG Altman, JAC Sterne Chapter 8: assessing risk of bias in included studies JPT Higgins S Green Cochrane Handbook for systematic reviews of interventions version 5.1.0 2011 Cochrane Collaboration
30. C Tudur Smith, PR Williamson A comparison of methods for fixed effects meta-analysis of individual patient data with time to event outcomes Clin Trials 4 2007 621 630
31. L Koopman, GJMG van der Heijden, AW Hoes, DE Grobbee, MM Rovers Empirical comparison of subgroup effects in conventional and individual patient data meta-analyses Int J Tech Assess Health Care 24 2008 358 361
32. CT Smith, PR Williamson, AG Marson Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes Stat Med 24 2005 1307 1319
33. D Kotecha, L Manzano, H Krum, DG Altman, J Holmes, M Flather The Beta-Blockers in Heart Failure Collaborative Group: individual patient data meta-analysis. PROSPERO register http://www.crd.york.ac.uk/PROSPERO/display-record.asp?ID=CRD42014010012 2014 (accessed July 27, 2014).
34. VL Roger, SA Weston, MM Redfield et al. Trends in heart failure incidence and survival in a community-based population JAMA 292 2004 344 350
35. SS Chugh, R Havmoeller, K Narayanan et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study Circulation 129 2014 837 847
36. Y Miyasaka, ME Barnes, BJ Gersh et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence Circulation 114 2006 119 125
37. MA Mamas, JC Caldwell, S Chacko, CJ Garratt, F Fath-Ordoubadi, L Neyses A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure Eur J Heart Fail 11 2009 676 683
38. S Stewart, N Murphy, A Walker, A McGuire, JJV McMurray Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK Heart 90 2004 286 292
39. D Cullington, KM Goode, J Zhang, JG Cleland, AL Clark Is heart rate important for patients with heart failure in atrial fibrillation? JACC Heart Fail 2 2014 213 220
40. EG Daoud, R Weiss, M Bahu et al. Effect of an irregular ventricular rhythm on cardiac output Am J Cardiol 78 1996 1433 1436
41. DM Clark, VJ Plumb, AE Epstein, GN Kay Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation J Am Coll Cardiol 30 1997 1039 1045
42. TG Neilan, RV Shah, SA Abbasi et al. The incidence, pattern, and prognostic value of left ventricular myocardial scar by late gadolinium enhancement in patients with atrial fibrillation J Am Coll Cardiol 62 2013 2205 2214
43. V Rudolph, RP Andrie, TK Rudolph et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation Nat Med 16 2010 470 474
44. M Komajda, F Follath, K Swedberg et al. The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe: part 2: treatment Eur Heart J 24 2003 464 474
45. M Komajda, O Hanon, M Hochadel et al. Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II Eur Heart J 30 2009 478 486
46. MJ Lenzen, E Boersma, WJ Reimer et al. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure Eur Heart J 26 2005 2706 2713
47. I Abi Nasr, A Bouzamondo, J-S Hulot, O Dubourg, J-Y Le Heuzey, P Lechat Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis Eur Heart J 28 2007 457 462
48. F Liu, Y Chen, X Feng, Z Teng, Y Yuan, J Bin Effects of beta-blockers on heart failure with preserved ejection fraction: a meta-analysis PLoS One 9 2014 e90555